Roche Investor Relations ASCO
نویسندگان
چکیده
Abstract 9025 Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with advanced non-small cell lung cancer (NSCLC). Poster Board #351 Abstract 9064 Updated efficacy and safety of the j-alex study comparing alectinib (ALC) with crizotinib (CRZ) in ALK-inhibitor naïve ALK fusion positive non-small cell lung cancer (ALK+ NSCLC). Poster Board #390 Abstract 9092 Atezolizumab (atezo) plus platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): Update from a phase Ib study. Poster Board #418
منابع مشابه
Roche presents new data for TECENTRIQ® (atezolizumab) and updates from across its cancer immunotherapy development programme at ASCO 2017
9092, Poster Board: #418. Lung Cancer—Non-Small Cell Metastatic Saturday 6 June, 08:00 – 11:30 CDT
متن کاملTalking up liquidity: insider trading and investor relations
Managements (“insiders”) of many corporations, especially small or newly-public firms, invest considerable resources in investor relations. We develop a model to explore the incentives of insiders to undertake such costly investments. We point out that insiders may undertake such investments not necessarily to improve the share price, but to enhance the liquidity of their block of shares. This ...
متن کاملRoche highlights personalised medicines and cancer immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
4515 (oral) Sunday, 5 June 08:00-11:00 CDT Abstract 9028 (poster) Saturday, 4th June 08:00-11:30 CDT9028 (poster) Saturday, 4th June 08:00-11:30 CDT Abstract 3005 (oral) Saturday, 4 June 13:15-16:15 CDT3005 (oral) Saturday, 4 June 13:15-16:15 CDT
متن کاملAn Empirial Investigation of the Relevance of Investor Relations
f * % An empirical investigation of the relevance of investor relations.
متن کامل